Literature DB >> 9841992

Effect of duodenal components of the refluxate on development of esophageal neoplasia in rats.

Y Yamashita1, K Homma, N Kako, G W Clark, T C Smyrk, R A Hinder, T E Adrian, T R DeMeester, S S Mirvish.   

Abstract

When duodenal content is allowed to reflux into the esophagus of nitrosamine-treated rats, esophageal cancer is induced more rapidly and at higher frequency than after carcinogen treatment alone. The purpose of the present study was to identify the components of the duodenal content that are responsible for enhancing esophageal carcinogenesis. Eight-week-old Sprague-Dawley rats underwent one of four operations as follows: diversion of bile alone, pancreatic juice alone, both bile and pancreatic juice into the esophagus, or a control operation with no induced reflux. Two weeks after surgery, rats were treated with the esophageal carcinogen 2, 6-dimethylnitrosomorpholine (48 mg/kg [0.1 of LD50] intraperitoneally weekly for 20 weeks). The rats were killed at age 30 weeks. The esophagus was removed and full-length strips were examined under a microscope; separate segments were taken for flow cytometric evaluation. The prevalence of DNA aneuploidy and histologic esophageal papillomas or squamous cancer was increased in carcinogen-treated rats with pancreatic juice reflux (P <0.05 vs. control) and the combination of pancreatic and bile reflux (P <0.05 vs. control) but not in rats with bile reflux alone. We conclude that pancreatic juice is the most potent component of the duodenal refluxate in the promotion of esophageal carcinogenesis in rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9841992     DOI: 10.1016/s1091-255x(98)80074-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  19 in total

1.  Influence of esophagojejunostomy on the induction of adenocarcinoma of the distal esophagus in Sprague-Dawley rats by subcutaneous injection of 2,6-dimethylnitrosomorpholine.

Authors:  M Pera; A Cardesa; J A Bombi; H Ernst; C Pera; U Mohr
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

2.  Esophagitis produced by reflux of duodenal contents in rats.

Authors:  M LEVRAT; R LAMBERT; G KIRSHBAUM
Journal:  Am J Dig Dis       Date:  1962-06

3.  Possible association between gastrectomy and subsequent development of esophageal cancer.

Authors:  M Maeta; S Koga; T Shimizu; K Matsui
Journal:  J Surg Oncol       Date:  1990-05       Impact factor: 3.454

4.  Carcinoma of the oesophagus after gastric surgery.

Authors:  D J Shearman; S J Arnott; N D Finlayson; J G Pearson
Journal:  Lancet       Date:  1970-03-21       Impact factor: 79.321

5.  Surgical therapy in Barrett's esophagus.

Authors:  T R DeMeester; S E Attwood; T C Smyrk; D H Therkildsen; R A Hinder
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

6.  Comparative carcinogenicity of two isomers of nitroso-2,6-dimethylmorpholine in guinea pigs.

Authors:  W Lijinsky; M D Reuber
Journal:  Cancer Lett       Date:  1981-10       Impact factor: 8.679

7.  Extensive dysplasia and carcinoma in situ of esophageal epithelium.

Authors:  S Ushigome; H J Spjut; G P Noon
Journal:  Cancer       Date:  1967-06       Impact factor: 6.860

8.  Active trypsin and reflux oesophagitis: an experimental study in rats.

Authors:  H J Mud; S E Kranendonk; H Obertop; H Van Houten; D L Westbroek
Journal:  Br J Surg       Date:  1982-05       Impact factor: 6.939

9.  Alkaline esophagitis: a comparison of the ability of components of gastroduodenal contents to injure the rabbit esophagus.

Authors:  K D Lillemoe; L F Johnson; J W Harmon
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

10.  Alkaline gastroesophageal reflux: implications in the development of complications in Barrett's columnar-lined lower esophagus.

Authors:  S E Attwood; T R DeMeester; C G Bremner; A P Barlow; R A Hinder
Journal:  Surgery       Date:  1989-10       Impact factor: 3.982

View more
  6 in total

1.  Barrett's esophagus and animal models.

Authors:  Ryan A Macke; Katie S Nason; Ken-ichi Mukaisho; Takanori Hattori; Takashi Fujimura; Shozo Sasaki; Katsunobu Oyama; Tomoharu Miyashita; Tetsuo Ohta; Koichi Miwa; Michael K Gibson; Ali Zaidi; Usha Malhotra; Ajlan Atasoy; Tyler Foxwell; Blair Jobe
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

2.  Serum pepsinogens and Helicobacter pylori in relation to the risk of esophageal squamous cell carcinoma in the alpha-tocopherol, beta-carotene cancer prevention study.

Authors:  Michael B Cook; Sanford M Dawsey; Lena Diaw; Martin J Blaser; Guillermo I Perez-Perez; Christian C Abnet; Philip R Taylor; Demetrius Albanes; Jarmo Virtamo; Farin Kamangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

3.  Does impaired gallbladder function contribute to the development of Barrett's esophagus and esophageal adenocarcinoma?

Authors:  Ayman O Nassr; Syeda Nadia Shah Gilani; Mohammed Atie; Tariq Abdelhafiz; Val Connolly; Neil Hickey; Thomas Noel Walsh
Journal:  J Gastrointest Surg       Date:  2011-04-12       Impact factor: 3.452

4.  Esophagogastric adenocarcinoma in an E1A/E1B transgenic model involves p53 disruption.

Authors:  M D Duncan; T Tihan; D M Donovan; Q H Phung; D L Rowley; J W Harmon; P J Gearhart; K L Duncan
Journal:  J Gastrointest Surg       Date:  2000 May-Jun       Impact factor: 3.452

5.  Establishing magnetic resonance imaging as an accurate and reliable tool to diagnose and monitor esophageal cancer in a rat model.

Authors:  Juliann E Kosovec; Ali H Zaidi; Yoshihiro Komatsu; Pashtoon M Kasi; Kyle Cothron; Diane V Thompson; Edward Lynch; Blair A Jobe
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

6.  High yield reproducible rat model recapitulating human Barrett's carcinogenesis.

Authors:  Daisuke Matsui; Ashten N Omstead; Juliann E Kosovec; Yoshihiro Komatsu; Emily J Lloyd; Hailey Raphael; Ronan J Kelly; Ali H Zaidi; Blair A Jobe
Journal:  World J Gastroenterol       Date:  2017-09-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.